Method of stabilizing and/or isolating nucleic acids
AssigneeQiagen GmbH
InventorsChristoph Erbacher, Helge Bastian, Ralf Wyrich, Uwe Oelmüller, Thomas Manz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of stabilizing and/or isolating nucleic acids, wherein a biological sample containing nucleic acids is contacted with a cationic compound. The invention also relates to said cationic compound per se and to the use of said cationic compound in stabilizing and/or isolating nucleic acids. Furthermore, the invention relates to pharmaceutical compositions, diagnostic compositions, and to compositions used in research, which include cationic compounds or a complex being formed upon contact of said cationic compound with a nucleic acid.
Claims34
A method of stabilizing unpurified nucleic acids in a biological sample from degradation comprising:
- contacting a biological sample containing unpurified nucleic acid with at least one cationic compound of formula (I)
- wherein (A) is an anion, and said anion is a conjugated base of a strong or weak inorganic or organic acid, or combinations thereof, and wherein the cationic compound (I) and anion (A), together, have a neutral charge,
- and wherein
- X is nitrogen (N),
- k is the integer 1, 2, 3, or 4,
- B represents a substituted or non-substituted aliphatic alkanediyl bridge, wherein the substituted aliphatic alkanediyl bridge is substituted on one or more carbon atoms, wherein one or more non-adjacent carbon atoms is replaced by oxygen, and wherein the substituted aliphatic alkanediyl bridge is the structure
- (CH2)n—(OCH2)m—
- wherein n and m independently represent the integer 0, 1, 2, 3, 4, 5, or 6, with n+m>0;
- R1, R2 and R3k, are independently selected from the group consisting of
- methyl, ethyl, propyl, isopropyl, butyl, isobutyl, n-pentyl, isopentyl, and hexyl
- RA, RBk, RC, are independently selected from the group consisting of an unsubstituted linear or branched C1-C21 alkyl, an unsubstituted linear or branched C1-C21 alkenyl, an unsubstituted linear or branched C1-C21 alkynyl,
- and a structure
- CH3—(CH2)n—Z—(CH2)m—
- wherein n, m are independent of each other, and n represents the integer 2, 3 or 4, m represents the integer 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18, and Z represents —O—, —CO—, —OCO—, —CO—N—, or —N—CO—;
- wherein the unpurified nucleic acid in the biological sample forms a complex with the cationic compound (1) and is stabilized from degradation within said biological sample;
- optionally concentrating the complexes of nucleic acid and cationic compound;
- storing the complex of nucleic acid and cationic compound until further tests are conducted or a further purification is performed;
- and
- optionally, isolating the stabilized nucleic acid from the biological sample.
A method of stabilizing unpurified nucleic acids in a biological sample from degradation comprising:
- contacting a biological sample containing unpurified nucleic acid with at least one cationic compound, wherein the cationic compound has the formula:
- wherein n is 1, 2, 3, or 4 and m is an integer between 8 and 20, inclusive.
A method of stabilizing unpurified nucleic acids in a biological sample from degradation comprising:
- contacting a biological sample containing unpurified nucleic acid with at least one cationic compound of formula (I)
- wherein (A) is an anion, and said anion is a conjugated base of a strong or weak inorganic or organic acid, or combinations thereof, and wherein the cationic compound (I) and anion (A), together, have a neutral charge,
- and wherein
- X is nitrogen (N),
- k is the integer 1, 2, 3, or 4,
- B represents a substituted or non-substituted aliphatic alkanediyl bridge, wherein the substituted aliphatic alkanediyl bridge is substituted on one or more carbon atoms, wherein one or more non-adjacent carbon atoms is replaced by oxygen, and wherein the substituted aliphatic alkanediyl bridge is the structure
- (CH2)n—(OCH2)m—
- wherein n and m independently represent the integer 0, 1, 2, 3, 4, 5, or 6, with n+m>0;
- R1, R2 and R3k, are independently selected from the group consisting of
- methyl, ethyl, propyl, isopropyl, butyl, isobutyl, n-pentyl, isopentyl, and hexyl
- RA, RBk, RC, are independently selected from the group consisting of an unsubstituted linear or branched C1-C21 alkyl, an unsubstituted linear or branched C1-C21 alkenyl, an unsubstituted linear or branched C1-C21 alkynyl, and a structure
- CH3—(CH2)n—Z—(CH2)m—
- wherein n, m are independent of each other, and n represents the integer 2, 3 or 4, m represents the integer 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18, and Z represents —O—, —CO—, —OCO—, —CO—N—, or —N—CO—;
- wherein the unpurified nucleic acid in the biological sample forms a complex with the cationic compound (1) and is stabilized from degradation within said biological sample;
- dissolving the complex between the cationic compound and the unpurified nucleic acid in the biological sample to liberate the nucleic acids under non-binding or binding conditions;
- and
- optionally, isolating the stabilized nucleic acid from the biological sample.
Dependencies are inferred from the claim text.